Pomerantz Law Firm's Investigation into Viking Therapeutics Raises Concerns for Investors

The Pomerantz Law Firm has initiated an investigation regarding potential claims on behalf of investors in Viking Therapeutics, Inc. (NASDAQ: VKTX). The investigation focuses on whether Viking, along with some of its key executives and directors, has been involved in securities fraud or other unlawful business activities.

On November 3, 2024, Viking Therapeutics made headlines with the announcement of positive trial results for VK2735, their new anti-obesity medication, during the Obesity Week medical meeting. This news resulted in an impressive uptick of 9% in the company’s stock price during intraday trading on November 4, 2024.

However, the excitement was short-lived, as industry analysts raised flags about potential manufacturing issues associated with VK2735, particularly concerning the production of higher dosage forms (100mg and above). In a note from Deutsche Bank, analysts highlighted the challenges and significant costs of scaling up production for VK2735. They pointed out that such requirements likely exceed the capabilities and resources available to major players like Eli Lilly and Novo Nordisk at this time.

In light of these concerns, Viking's stock price suffered a fall, plummeting $9.74, or 13.36%, closing at $63.14 on November 4, 2024. Investors are advised to remain vigilant and consider the ramifications of the ongoing investigation led by Pomerantz LLP, a well-established firm with a solid reputation in corporate, securities, and antitrust litigation. Founded over 85 years ago by the late Abraham L. Pomerantz, the firm has a long history of advocating for victims of securities fraud and corporate misconduct.

Pomerantz has successfully secured billions of dollars in damages for class members, underscoring its commitment to protecting investor interests. Investors of Viking Therapeutics are encouraged to reach out to Pomerantz to explore their options regarding joining the class action lawsuit.

With the medical landscape continually evolving, the outcome of this investigation might have significant implications for Viking Therapeutics and its investors. As the market watches closely to see how the company addresses production concerns and regulatory scrutiny, stakeholders must stay informed to mitigate potential risks associated with their investments.

For those interested in learning more about the investigation or potentially participating in the class action, Pomerantz LLP invites investors to contact Danielle Peyton directly via email or phone. As a trailblazer in the field of securities class actions, Pomerantz’s initiatives remind all stakeholders of the importance of vigilance and due diligence in the investment realm.